

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claims 1-286 (canceled)

287. (new) A method of inducing tumor tissue regression in a patient comprising administering to said patient a therapeutically effective amount of an antibody immunospecific for $\alpha_v\beta_3$.

288. (new) The method of claim 287 wherein said antibody is a monoclonal antibody.

289. (new) The method of claim 287 or 288 wherein said tissue is a solid tumor tissue.

290. (new) The method of claim 287 or 288 wherein said tumor tissue is bladder.

291. (new) The method of claim 287 or 288 wherein said tumor tissue is breast.

292. (new) The method of claim 287 or 288 wherein said tumor tissue is colon.

293. (new) The method of claim 287 or 288 wherein said tumor tissue is lung.

294. (new) The method of claim 287 or 288 wherein said tumor tissue is skin.

295. (new) The method of claim 287 or 288 wherein said tumor tissue is a carcinoma.

296. (new) The method of claim 287 or 288 wherein said tumor tissue is a melanoma.

297. (new) The method of claim 287 or 288 wherein said administering comprises intravenous administration.

298. (new) The method of claim 287 or 288 wherein said administering comprises oral administration.

299. (new) The method of claim 287 or 288 wherein said administering comprises transdermal administration.

300. (new) The method of claim 287 or 288 wherein said administering comprises intramuscular administration.

301. (new) The method of claim 287 or 288 wherein said administering comprises subcutaneous administration.

302. (new) The method of claim 287 or 288 wherein said administering comprises intracavity administration.

Sub H1

f

✓ 303. (new) The method of claim 287 or 288 wherein said administering comprises peristaltic administration.

✓ 304. (new) The method of claim 287 or 288 wherein said administering comprises parenteral administration.

✓ 305. (new) The method of claim 287 or 288 wherein said administering comprises systemic administration.

✓ 306. (new) The method of claim 287 or 288 wherein said administering comprises administration by gradual infusion.

✓ 307. (new) The method of claim 287 or 288 wherein said administering comprises one or more dose administrations daily, for one or several days.

✓ 308. (new) The method of claim 287 or 288 wherein said administering comprises a single dose.

✓ 309. (new) The method of claim 287 or 288 wherein said amount is from about 0.1 mg/kg to about 300 mg/kg patient body weight.

✓ 310. (new) The method of claim 287 or 288 wherein said amount is from about 0.2 mg/kg to about 200 mg/kg patient body weight.

✓ 311. (new) The method of claim 287 or 288 wherein said amount is from about 0.5 mg/kg to about 20 mg/kg patient body weight.

✓ 312. (new) The method of claim 287 or 288 wherein said administering is conducted in conjunction with chemotherapy.

✓ 313. (new) The method of claim 287 or 288 wherein the patient is human.

✓ 314. (new) The method of claim 287 or 288 wherein the patient is a patient with angiofibromas.

✓ 315. (new) The method of claim 287 or 288 wherein the patient is a patient with retrosternal fibroplasia.

✓ 316. (new) The method of claim 287 or 288 wherein the patient is a patient with hemangiomas.

✓ 317. (new) The method of claim 287 or 288 wherein the patient is a patient with Karposi sarcoma.

✓ 318. (new) The method of claim 287 or 288 wherein said antibody preferentially inhibits fibrinogen binding to $\alpha_v\beta_3$ compared to fibrinogen binding to $\alpha_{IIb}\beta_3$.

F

~~33~~ 319. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody specifically binds $\alpha_v\beta_3$ complex.

~~34~~ 320. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody is an antibody fragment.

~~35~~ 321. (new) The method of claim ~~320~~ wherein said antibody is a Fab fragment.

~~36~~ 322. (new) The method of claim ~~320~~ wherein said antibody is a Fab' fragment.

~~37~~ 323. (new) The method of claim ~~320~~ wherein said antibody is a $F(ab')_2$ fragment.

~~38~~ 324. (new) The method of claim ~~320~~ wherein said antibody is a $F(v)$ fragment.

~~39~~ 325. (new) The method of claim ~~288~~ wherein said monoclonal antibody has the binding specificity of the monoclonal antibody LM609 having ATCC accession number HB 9537.

~~40~~ 326. (new) The method of claim ~~288~~ wherein said monoclonal antibody is humanized.

~~41~~ 327. (new) The method of claim ~~287~~ or ~~288~~ wherein said tumor tissue is metastatic.

~~42~~ 328. (new) The method of claim ~~287~~ or ~~288~~ wherein said antibody is administered in a composition.

~~43~~ 329. (new) The method of claim ~~328~~ wherein said composition is a sterile pharmaceutical composition.

~~44~~ 330. (new) The method of claim ~~287~~ or ~~288~~ wherein said administering is conducted following surgery.

~~45~~ 331. (new) The method of claim ~~287~~ or ~~288~~ wherein said patient was previously treated for a first tumor.

~~46~~ 332. (new) The method of claim ~~331~~ wherein said first tumor is a solid tumor.

~~47~~ 333. (new) The method of claim ~~331~~ wherein said first tumor is a carcinoma.

~~48~~ 334. (new) The method of claim ~~331~~ wherein said first tumor is a melanoma.

~~49~~ 335. (new) The method of claim ~~331~~ wherein said patient previously underwent surgery to remove said first tumor.

~~50~~ 336. (new) The method of claim ~~331~~ wherein said patient was previously treated with chemotherapy.

~~51~~ 337. (new) A method of inducing solid tumor tissue regression in a human patient in need thereof, said method comprising administering to said human patient a therapeutically effective amount of a humanized monoclonal antibody immunospecific for $\alpha_v\beta_3$ complex.

~~52~~ 338. (new) The method of claim ~~337~~ wherein said humanized monoclonal antibody has the

binding specificity of the monoclonal antibody LM609 having ATCC accession number HB9537.

~~5339.~~ (new) The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a melanoma. ⁵¹ ⁵²

~~51~~ ~~340.~~ (new) The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a carcinoma. ⁵¹ ⁵²

~~51~~ ~~341.~~ (new) The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a skin carcinoma solid tissue tumor. ⁵¹ ⁵²

~~51~~ ~~342.~~ (new) The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a bladder carcinoma solid tissue tumor. ⁵¹ ⁵²

~~51~~ ~~343.~~ The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a breast carcinoma solid tissue tumor. ⁵¹ ⁵²

~~50~~ ~~344.~~ The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a colon carcinoma solid tissue tumor. ⁵¹ ⁵²

~~51~~ ~~345.~~ The method of claim ~~327~~ or ~~328~~ wherein said tumor tissue is a lung carcinoma solid tissue tumor. ⁵¹ ⁵²